Phospho-TOP2A (Thr1343) Antibody

1. The highly proliferating C2A subtype of hepatoblastoma is characterized by topoisomerase 2-alpha gene up-regulation and Fanconi anemia pathway activation. PMID: 29152775
2. TOP2A protein showed a time dependent influence on prognosis in stage I-II luminal breast cancer, suggesting it might be a potential predictor of late recurrence for this group of patients. PMID: 29587760
3. Data indicate that tyrosyl-DNA phosphodiesterase 2 (TDP2) alone does not remove DNA topoisomerase II (TOP2)-DNA complexes from genomic DNA in vitro and that depletion of TDP2 in cells does not slow the removal of TOP2-DNA complexes. PMID: 30011940
4. High TOP2A expression and Gene Amplification is associated with Upper Tract Urothelial Carcinomas. PMID: 28755093
5. Ki-67 and TOPO 2A expression correlated with tumour size and tumour invasiveness in somatotropinomas. PMID: 29334118
6. RNF168 interacts with TOP2alpha to mediate its polyubiquitylation and RNF168 deficiency confers resistance to ICRF-193, a TOP2 catalytic inhibitor, and cytotoxic anti-cancer drug etoposide in cultured mouse cells. PMID: 27558965
7. we show that despite being more cytotoxic, F14512 is less efficient than etoposide at producing TOP2alpha cleavage-complex (TOP2alphacc) in cells PMID: 28611105
8. our data support further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neoadjuvant targeted therapy approaches PMID: 28899973
9. High mRNA levels of TOP2A is independent predictor of poor outcome in Renal Cell Carcinoma patients. PMID: 28069330
10. findings implicate TOP2A cleavage as a broad DNA damage mechanism in oncogenic translocations as well as a functional role of TOP2A cleavage in regulating transcription elongation and gene activation. PMID: 28385713
11. TOP2A acts as a co-activator of beta-catenin and activates Epithelial-mesenchymal transition process. PMID: 29045811
12. ProEx C is an immunohistochemical cocktail containing antibodies direct against topoisomerase IIalpha (TOP2A) and minichromosome maintenance 2 (MCM2) proteins. This brief review covers the effective utility of ProEx C as adjunct tool in assessing the urothelial lesions in urine cytology, also providing prognostic and therapeutic information to help in clinical decisions. PMID: 28638271
13. High TOP2A expression was significantly associated with longer time to progression after EDP-M. TOP2A and TS proteins assessed by immunohistochemistry significantly correlated with mRNA expression. Immunohistochemical TOP2A expression was associated with a non-significant better response and longer TTP after EDP-M. PMID: 28432084
14. Data show that comparing with Ki-67 and TOP2A, RacGAP1 allowed for a clearer prognostic statement. PMID: 27259241
15. These findings reveal a novel, p53-independent activity of Mdm2 and have important implications for the choice of chemotherapeutic agents in the treatment of Mdm2-overexpressing tumors. Herein is shown that tumor cells with MDM2 amplification are selectively resistant to treatment with topoisomerase II poisons but not other DNA damaging agents PMID: 28692049
16. The methodology is useful for a high-throughput analysis of drugs that poison Top2, allowing not just the discrimination of the Top2 isoform that is targeted but also to track its removal PMID: 27517472
17. TOP2A was identified in association with the progression and prognosis of pancreatic ductal adenocarcinoma probably by regulating cell cycle and p53 signaling pathway. PMID: 28815403
18. the relation between TOP2A levels and sensitivity for doxorubicin was examined, confirming reports that TOP2A mRNA levels were overexpressed in MPNST and showing that MPNST cell lines exhibited relatively high TOP2A protein levels and sensitivity to doxorubicin. PMID: 28813519
19. The decatenation checkpoint is regulated, not only by topo IIalpha, as previously reported, but also by topo IIbeta. The decatenation checkpoint is most efficient when both isoforms are present. Deletion of most of the C-terminus of topo IIalpha, while preserving the nuclear localization signal (NLS), enhances the decatenation checkpoint and sensitivity to topo II-targeted drugs. Mutation of Y640 in topo IIalpha inhibi... PMID: 28472494
20. Tumors with higher topoisomerase IIalpha and/or mitosin expression have a higher risk of recurrence after initial treatment, and these patients may benefit from adjuvant treatment and closer radiological follow-up PMID: 28301542
21. Both the genome instability and cell death of MRE11-null and MRE11-mutated H129N cells are significantly reversed by overexpression of Tdp2, an enzyme that eliminates covalent Top2 conjugates; thus, the essential role of Mre11 nuclease activity is likely to remove the DNA lesions. PMID: 27814490
22. Topoisomerase-IIalpha expression was identified as a predictor of disease-free survival in high grade papillary urothelial carcinomas. PMID: 27473264
23. This study shows that both survivin and TIIalpha are independent prognostic predictors in human grade II/III astrocytomas stratified for IDH1-mutation status PMID: 28214203
24. Polyamide functionalisation at the N1-position offers a design strategy to improve drug-like properties. Dicationic HxIP* 3 increased topo IIalpha expression and chemosensitivity to topo II-targeting agents. PMID: 27750031
25. These results explain why hTOPIIa and hTOPIIa are differentially affected by various poisons and demonstrate the utility of C. elegans in understanding the genetics of drug responses. PMID: 28700616
26. BD ProExtrade mark C assay containing MCM2 and TOP2A antibodies showed strong specific nuclear staining that correlated with increased cervical dysplasia and lesion severity. PMID: 28093271
27. Fbxo28 regulates topoisomerase IIalpha decatenation activity and plays an important role in maintaining genomic stability. PMID: 27754753
28. TOP2A rs471692 was not associated with chemoradiotherapy response, whereas tumor regression, weight loss, clinical stage, and cigarette smoking were independent prognostic predictors for these Chinese patients with non-small cell lung cancer. PMID: 28231233
29. we propose that phosphorylation of TOP2A by CDC7/DBF4 in early S-phase prevents its localization and/or activity at centromeres, and inhibition of TOP2A function could be relevant to prevent premature separation of centromeric DNA. PMID: 27407105
30. Data indicate that cortex involvement, lower World Health Organization grade and DNA topoisomerase II positivity were strong predictors for preoperative epileptic seizures. PMID: 28087392
31. Alternative RNA Processing of Topoisomerase IIalpha in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform PMID: 27974648
32. Study found an association between TOP2alpha gene amplification and overexpression of its protein in patients with triple-negative breast cancer. PMID: 28393224
33. This study showed that the overexpressions of Ki67, RacGAP1, and TOP2a affect the prognosis of female breast cancer patients adversely PMID: 27284123
34. TOP2A is highly expressed in advanced leiomyosarcoma (LMS)but not in non-malignant diseases. TOP2A levels are higher in high-mitotic index tumours and in more advanced stages of disease. PMID: 26994023
35. TOP2a involvement in breast cancer cells apoptosis PMID: 28075472
36. HER2 amplification, but not TOP2A amplification, is a predictor of unfavorable prognosis in breast cancer. PMID: 28079792
37. TOP2A and Ki-67 antibodies may be used in combination for cervical cancer screening in immunocytochemistry assays. PMID: 27175798
38. The combined quantum and molecular mechanics calculations revealed that CF3 containing drug shows better preference in inhibiting the TOP2A compared to other modified drugs. PMID: 27088089
39. Positive expressions of MRP and TOP2A in the tumor tissue are associated with increased risk of developing brain metastases in non-small cell lung cancer (NSCLC). PMID: 26617887
40. may be a useful biomarker in patients receiving adjuvant taxane-platinum regimens with moderate- to high-risk endometrial cancer PMID: 26588239
41. during early development, TOP2A is likely to have a role in cell proliferation, whereas TOP2B is expressed in post-mitotic cells and may be important in controlling expression of long genes even at this early stage. PMID: 26612825
42. Deletion or deficiency of PTEN leads to down regulation of TOP2A, dysfunction of the decatenation checkpoint and incomplete DNA decatenation in G2 and M phases. PMID: 26657567
43. The study is an open label, single arm, phase II study, investigating the efficacy of epirubicin in patients with oxaliplatin refractory colorectal cancer and with a cancer cell TOP2A/CEN-17 ratio >/= 1.5 PMID: 26867764
44. These studies revealed a relationship between TOP2A and androgen receptor signaling pathway that contributes to prostate cancer progression and confers sensitivity to treatments. PMID: 26560244
45. TUBB3, TOP2A, CYP19A1 and CYP2D6 gene expression, but not protein expression, was associated with patient survival in breast cancer . PMID: 26252353
46. PICH and Topo II cooperate to prevent chromosome missegregation events in mitosis. PMID: 26643143
47. Topoisomerase IIalpha, an enzyme essential for resolution of DNA replication intermediates, binds telomeres in a TRF1-mediated manner. PMID: 24626180
48. Mutation in TOP2A gene is associated with epithelial ovarian cancer growth and drug resistance. PMID: 25846551
49. Patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition. PMID: 25605014
50. It might, therefore, be concluded that topoisomerase II enzyme may be involved in the repair of radiation-induced DNA damage and consequently its inhibition constitute a strategy for sensitizing tumour cells to ionizing radiation. PMID: 26081617

Show More

Hide All

HGNC: 11989

OMIM: 126430

KEGG: hsa:7153

STRING: 9606.ENSP00000411532

UniGene: Hs.156346